# Aquestive Therapeutics (TSX:Not available)

> Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.

## About

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. With proprietary technologies like PharmFilm® and AdrenaVerse™, we’re advancing patient-friendly alternatives to inconvenient or invasive therapies, including investigational treatments for anaphylaxis and potentially alopecia areata. Our expertise spans the full product lifecycle, from formulation to commercialization, with four commercialized products marketed by our licensees in the U.S. and around the world. We have the expertise to manufacture and package a wide range of pharmaceutical products, including oral films, creams, and lotions, for our contract licensees and customers. Since the inception of the Company, we have been committed to our purpose: developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.

## Key facts

- **Cash position:** $110.7 million
- **Shares outstanding:** 99,723,635
- **Fully diluted shares:** N/A
- **Warrants:** 2,750,000
- **Options:** 35,000
- **Projects:** ["Anaphylm™ (dibutepinephrine) sublingual film\nPotential Indication\nType 1 allergic reactions, including anaphylaxis\nPre-ClinicalPhase 1Phase 2Phase 3\nAn oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.\n[Learn more](https://aquestive.com/anaphylm)","AQST-108 (epinephrine) topical gel\nPotential Indication\n(multiple potential indications)\nPre-ClinicalPhase 1Phase 2Phase 3","Libervant® (diazepam) buccal film\nPotential Indication\nAcute repetitive seizures / cluster seizures\nPre-ClinicalPhase 1Phase 2Phase 3\nAn oral film formulation of diazepam being developed as a rescue therapy for intermittent, stereotypic episodes of frequent seizure activity (also known as seizure clusters) in patients with epilepsy.\n[Learn more](https://aquestive.com/libervant)"]
- **Leadership:** Dan Barber (President and Chief Executive Officer, Experienced leader in the pharmaceutical industry with a focus on innovation and patient care.), Peter Boyd (Chief People Officer), Melina T. Cioffi, Pharm.D. (Senior Vice President – Regulatory Affairs), Matthew W. Davis, M.D., RPh (Chief Development Officer), Matthew Greenhawt, M.D. (Chief Medical Officer), Cassie Jung (Chief Operating Officer), Sherry Korczynski (Chief Commercial Officer), Ernie Toth (Chief Financial Officer), Thomas A. Zalewski (Chief Legal Officer and Chief Compliance Officer), Gregory B. Brown, M.D. (Chair of the Board, Co-founder of HealthCare Royalty Partners), John Cochran (Director, Partner at Bratton Capital Management L.P.), Abigail L. Jenkins (Director, former President & CFO of Gamida Cell Ltd.), Julie Krop, M.D. (Director, Chief Medical Officer of DiaMedica Therapeutics, Inc.), Timothy E. Morris (Director, Chief Operating Officer of Humanetics Corporation), Marco Taglietti, M.D. (Director, Chief Executive Officer of NanoNewron)

_Verified data last updated: 2026-07-17_

## Investor FAQ

### [Upcoming catalysts?](https://chat.orbiton.app/aqst/faq/upcoming-catalysts)

Not disclosed in available filings.

### [Latest news?](https://chat.orbiton.app/aqst/faq/latest-news)

Not disclosed in available filings.

## Live AI chat

- https://chat.orbiton.app/aqst/chat
- Investor website: https://aquestive.com/